NO20076119L - Diagnostisk markor for diabetiske vaskulaere komplikasjoner - Google Patents

Diagnostisk markor for diabetiske vaskulaere komplikasjoner

Info

Publication number
NO20076119L
NO20076119L NO20076119A NO20076119A NO20076119L NO 20076119 L NO20076119 L NO 20076119L NO 20076119 A NO20076119 A NO 20076119A NO 20076119 A NO20076119 A NO 20076119A NO 20076119 L NO20076119 L NO 20076119L
Authority
NO
Norway
Prior art keywords
diagnostic marker
vascular complications
diabetic vascular
diabetic
complications
Prior art date
Application number
NO20076119A
Other languages
English (en)
Inventor
William R Usinger
Ayad A Jaffa
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of NO20076119L publication Critical patent/NO20076119L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Foreliggende oppfinnelse gjelder den oppdagelse at CTGF er en diagnostisk markør som indikerer forhøyet risiko for utvikling og progresjon av karsykdom.
NO20076119A 2005-05-05 2007-11-27 Diagnostisk markor for diabetiske vaskulaere komplikasjoner NO20076119L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67825105P 2005-05-05 2005-05-05
PCT/US2006/017755 WO2006122043A2 (en) 2005-05-05 2006-05-05 Diagnostic marker for diabetic vascular complications

Publications (1)

Publication Number Publication Date
NO20076119L true NO20076119L (no) 2008-01-30

Family

ID=37343788

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076119A NO20076119L (no) 2005-05-05 2007-11-27 Diagnostisk markor for diabetiske vaskulaere komplikasjoner

Country Status (11)

Country Link
US (1) US20090325302A1 (no)
EP (1) EP1889072A2 (no)
JP (1) JP2008541062A (no)
CN (1) CN101213456A (no)
AU (1) AU2006244144A1 (no)
CA (1) CA2606812A1 (no)
IL (1) IL187114A0 (no)
MX (1) MX2007013831A (no)
NO (1) NO20076119L (no)
WO (1) WO2006122043A2 (no)
ZA (1) ZA200710199B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011523051A (ja) * 2008-05-20 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
KR101249041B1 (ko) * 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
US20130177544A1 (en) * 2010-09-21 2013-07-11 The University Of Western Australia Biomarkers associated with pre-diabetes, diabetes and diabetes related conditions
JP6128631B2 (ja) * 2012-08-01 2017-05-17 国立大学法人名古屋大学 糖尿病性腎症鑑別用マーカー及びその用途
CN106906278A (zh) * 2015-12-22 2017-06-30 复旦大学 预测ii型糖尿病心血管并发症风险的生物标记物及其用途
CN109411062A (zh) * 2018-09-30 2019-03-01 天津科技大学 一种基于深度学习技术利用生理参数自动判断糖尿病及其并发症的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1326361A (zh) * 1998-09-08 2001-12-12 亨利福特保健系统公司 通过修饰、调节及抑制结缔组织生长因子来检查、预防和治疗肾脏疾病的方法
US20030113816A1 (en) * 2001-09-18 2003-06-19 Weitz Stephen L. Methods of assaying connective tissue growth factor
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes

Also Published As

Publication number Publication date
ZA200710199B (en) 2009-06-24
US20090325302A1 (en) 2009-12-31
MX2007013831A (es) 2008-02-05
CA2606812A1 (en) 2006-11-16
EP1889072A2 (en) 2008-02-20
WO2006122043A2 (en) 2006-11-16
JP2008541062A (ja) 2008-11-20
CN101213456A (zh) 2008-07-02
WO2006122043A3 (en) 2007-03-29
AU2006244144A1 (en) 2006-11-16
IL187114A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
NO20076119L (no) Diagnostisk markor for diabetiske vaskulaere komplikasjoner
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
ATE516746T1 (de) Vorrichtung für die kontinuierliche, nicht- invasive messung des arteriellen blutdrucks und ihre verwendung
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
BRPI0610308A8 (pt) Composições e métodos para o tratamento de doença retinal
EA200802213A1 (ru) Способы лечения заболеваний крови
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005002930D1 (de) Sulfonamidderivate zur behandlung von krankheiten
GT200600109A (es) Derivados de acido pirimidincarboxilico y su uso
DE102005024352B8 (de) Medizinisches Instrument für endoskopische Eingriffe
CL2008000594A1 (es) Uso de compuestos derivados de heterociclos; composicion farmaceutica que comprende a dichos compuestos y otros agentes activos; y su uso para tratar diabetes, enfermedad arterial coronaria entre otras enfermedades.
ATE499344T1 (de) Peri-substituierte bicyclische sulfonamide gegen arterielle verschlusskrankheit
ATE499070T1 (de) Saugstent
NO20082904L (no) Feksofenadinsupensjonsformulering
EP2293077A3 (en) Methods for detecting coronary artery disease
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
CY1116938T1 (el) Αναπληρωτικη θεραπεια της ασθενειας huntington και αλλων ασθενειων πολυγλουταμiνης
CY1116840T1 (el) Χρηση 24-norudca
EA200900261A1 (ru) Применение эсцина
EA200801425A1 (ru) Диазепиноны
DE502005008610D1 (de) Spreizbares medizinisches Instrument für endoskopische Eingriffe
WO2010115034A3 (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
DK1251875T3 (da) Anvendelse af kontrastmidler til fremstilling af et diagnostisk middel til visualisering af intestinallumen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application